Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?

Recorded April 21, 2020.

Multiple Myeloma
COVID-19

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.

Global Cancer Care
COVID-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement